GlassScriptPhysician profile
Nicholas Panagiotis
NPI 1255313458
$3,423.56
in general payments reported to CMS, 2019-2025
37 companies · $913 in 2025
The $913 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $262 · 2021: $440 · 2022: $570 · 2023: $480 · 2024: $370 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,739 · Education: $24.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,738.78 |
| Education | $24.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $378.16 | 2019-2025 | Jardiance, Zepbound |
| Amgen INC. | $316.44 | 2019-2025 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.51 | 2022-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $235.90 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $228.49 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Novartis Pharmaceuticals Corporation | $221.44 | 2021-2025 | |
| Mannkind Corporation | $206.69 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $184.40 | 2019-2022 | |
| Abbvie INC. | $166.92 | 2019-2021 | |
| Dexcom, INC. | $113.40 | 2020-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $97.85 | 2024-2025 | |
| Madrigal Pharmaceuticals | $96.01 | 2025 | Rezdiffra |
| Corcept Therapeutics | $90.27 | 2022-2025 | Korlym |
| Insulet Corporation | $89.72 | 2025 | Omnipod |
| Kyowa Kirin, INC. | $68.03 | 2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $59.91 | 2021-2023 | Nexletol |
| Merck Sharp & Dohme LLC | $52.23 | 2022-2025 | Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $50.11 | 2023 | |
| Ibsa Pharma INC. | $47.50 | 2020-2025 | Flector, Licart, Tirosint |
| Horizon Therapeutics Plc | $44.62 | 2022-2023 | Tepezza |
| Pfizer INC. | $44.22 | 2019-2023 | |
| Emd Serono, INC. | $44.11 | 2024 | |
| Xeris Pharmaceuticals, INC. | $31.73 | 2021-2022 | |
| Boston Scientific Corporation | $29.04 | 2020 | |
| Tolmar, INC. | $28.21 | 2025 | Jatenzo |
| Sequel Med Tech, LLC | $25.35 | 2025 | Twiist |
| Chiesi USA, INC. | $22.91 | 2025 | Myalept, Juxtapid |
| Ultragenyx Pharmaceutical INC. | $22.36 | 2021 | |
| Alexion Pharmaceuticals, INC. | $22.29 | 2021 | |
| Astellas Pharma US INC | $21.50 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.92 | 2019 | |
| Acorda Therapeutics, INC | $18.53 | 2022 | |
| Amryt Pharma Holdings LTD | $16.51 | 2022 | |
| Glaxosmithkline, LLC. | $16.00 | 2024 | Trelegy Ellipta, Arexvy |
| Cequr Corporation | $14.53 | 2025 | Cequr Simplicity |
| Medtronic Minimed, INC. | $12.46 | 2019 | |
| Acadia Pharmaceuticals INC | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Panagiotis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.